论文部分内容阅读
目的研究前列地尔注射液治疗2型糖尿病合并脑梗死患者的临床疗效及其对血清炎性因子白细胞介素6(IL-6)及可溶性细胞间黏附分子-1(sICAM-1)表达的影响。方法选取2013年7月~2015年3月本院收治的2型糖尿病合并脑梗死患者98例,随机均分为对照组和治疗组,对照组进行常规治疗,治疗组在对照组治疗基础上加用前列地尔注射液,观察患者的总体疗效、神经功能与生活能力改善情况、炎性因子表达、不良反应。结果治疗后治疗组总有效率(91.84%)明显高于对照组(77.55%),差异具有统计学意义(P<0.05);与对照组治疗后比较,治疗组患者生活活动能力评分显著增加,神经功能缺损评分显著减小,差异均具有统计学意义(P<0.05);与对照组治疗后比较,sICAM-1、IL-6水平明显下降(P<0.01);治疗组与对照组药物治疗安全性比较,差异无统计学意义(P>0.05)。结论前列地尔注射液治疗2型糖尿病合并脑梗死患者效果显著,改善患者神经功能,可能与抑制炎性因子表达有关。
Objective To investigate the clinical efficacy of alprostadil injection in the treatment of type 2 diabetes mellitus patients with cerebral infarction and its effect on the expression of interleukin 6 (IL-6) and soluble intercellular adhesion molecule-1 (sICAM-1) . Methods From July 2013 to March 2015, 98 patients with type 2 diabetes mellitus complicated with cerebral infarction admitted to our hospital were randomly divided into control group and treatment group. The control group was treated routinely. The treatment group was treated on the basis of the control group With alprostadil injection to observe the patient’s overall efficacy, improved neurological function and viability, inflammatory factor expression, adverse reactions. Results After treatment, the total effective rate (91.84%) in the treatment group was significantly higher than that in the control group (77.55%), the difference was statistically significant (P <0.05). Compared with the control group, the activity score of the patients in the treatment group increased significantly (P <0.05). Compared with the control group, the levels of sICAM-1 and IL-6 were significantly decreased (P <0.01). The treatment group and the control group were significantly lower than those of the control group Safety comparison, the difference was not statistically significant (P> 0.05). Conclusion Alprostadil injection in the treatment of type 2 diabetes mellitus patients with cerebral infarction has a significant effect on improving neurological function, which may be related to inhibiting the expression of inflammatory cytokines.